WHO ICTRP trial
Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in…
CTIS2024-512912-23-00 · EU Clinical Trials Information System · Not Recruiting
Key facts
| Trial ID | CTIS2024-512912-23-00 |
|---|---|
| Public title | Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fed Conditions |
| Scientific title | - BLCL-LEN-FDA-02 |
| Primary sponsor | Bluepharma Industria Farmaceutica S.A. |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): Yes Therapeutic exploratory (Phase II): No Therapeutic confirmatory - (Phase III): No Therapeutic use - (Phase IV): No |
| Countries | Portugal |
| Conditions | No medical condition;Therapeutic area: Not possible to specify |
| Registration date | Mar 5, 2024 |
| Target size | 30 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: